14 results about "Nifedipine" patented technology

The invention belongs to the technical field of medical drugs, and discloses a nifedipine biphase sustained release preparation and a preparation method thereof. The nifedipine biphase sustained-release preparation consists of a double-layer tablet core and a film coating, wherein the double-layer tablet core consists of a drug-containing quick-release layer and a drug-containing sustained-release layer; nifedipine is respectively dispersed in the sustained-release layer and the quick-release layer according to a certain proportion. The biphasic sustained release preparation provided by the invention can take effect quickly, has stable and lasting drug effect, is safe and reliable, and is simple and efficient in preparation process.

The invention relates to the technical field of pharmaceutical preparations, and discloses a nifedipine controlled-release pellet capsule and a preparation method thereof. The nifedipine pellet is prepared from nifedipine, a hydrophilic swelling carrier, a hydrophobic structure framework material, an interface stabilizer, namely hydrophobic fumed silica, and a solubilizer. A step-by-step pre-dispersion and hot-melt co-extrusion combined process is adopted, a modified lipid intermediate containing an interface stabilizer is firstly prepared, and then the modified lipid intermediate and a drug-containing hydrophilic premix are co-extruded. According to the method, an interface pinning effect is generated by utilizing enrichment of an interface stabilizer on a two-phase interface, and a stable microcosmic bicontinuous phase skeleton structure is constructed. The structure utilizes the physical barrier and zigzag pore effect of the lipid skeleton, and can realize zero-order stable release of the drug without coating. The problems of burst release risk and ethanol-induced dosage dumping of a traditional preparation are effectively solved, the process is continuous and efficient, and the product reproducibility is good.

The application discloses a coating composition of nifedipine sustained-release tablets, a preparation method and a coating process. The composition comprises HPC-L, HPC-M, polydopamine, PVP K30 and hydrophilic nanosilica, and can improve the hydration coordination of the coating layer, the film stability and the sustained-release stability.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a nifedipine tablet and a preparation method thereof. The nifedipine tablet comprises nifedipine, a composite sustained-release material, a filler, an adhesive and a lubricant, the composite sustained-release material comprises a polylactic acid-glycolic acid copolymer, a polyethylene glycol-polylactic acid copolymer, chitosan, alginate and calcium salt. PLGA ensures that the in-vivo degradation period is matched with the requirement of 24-hour release of nifedipine, and the dispersibility and water solubility of nifedipine are improved by utilizing the amphipathy of PEG-PLA; the chitosan and nifedipine form a complex due to the positive charge characteristic, so that the crystal form transformation of the medicine is inhibited; alginate is rapidly gelated under the action of calcium ions, and cooperates with PEG-PLA to regulate and control the initial release rate, so that burst release is avoided. A novel composite sustained-release material is adopted and is matched with a specific preparation process, so that the comprehensive effects of 24-hour constant-speed release, high bioavailability and excellent stability can be realized.

The present application relates to a kind of poorly soluble drug osmotic pump controlled-release tablets and its preparation method, the osmotic pump controlled-release tablets include tablet core, semi-permeable membrane coating and release hole, the tablet core includes solid dispersion of poorly soluble drug and penetration agent, the solid dispersion of poorly soluble drug includes poorly soluble drug and carrier, the poorly soluble drug is selected from nicardipine, nifedipine, felodipine and their pharmaceutically acceptable salt, the carrier is selected from organic acid substance.Compared with prior art, the poorly soluble drug osmotic pump controlled-release tablets of the present application greatly improves the drug solubility, without using a large amount of penetration agent or other excipients in tablet core, drug loading is increased, and tablet core will not be too large;In vivo release greatly improves;Preparation process is simple, equipment requirement and cost are low, and easy to industrialization.

A biodegradable bio-scaffold patch for topical application, consisting of a porous chitosan alginate layer and a poly(lactic acid) carrier layer, wherein the porous layer encapsulates an active ingredient selected from amlodipine, nifedipine or prazosin, and the patch is configured to allow controlled release onto the skin over varicose veins.

This invention discloses an antibacterial spinning oil suitable for acetate fibers used in cigarette filters, comprising an emulsifier, mineral oil, water, and an antibacterial agent. Before phase inversion, it is a transparent water-in-oil liquid; after phase inversion, it becomes a white oil-in-water emulsion. Phase inversion occurs in water or water containing the antibacterial agent. The mass ratio of the spinning oil to the water used for phase inversion or water containing the antibacterial agent before phase inversion is (1–49):(99–51). The antibacterial agent is a commercially available water-soluble antibacterial agent, selected from one or more of the following: 4-chloro-3-cresol, dichlorophenoxychlorophenol, bromochlorobisphenol, benzyl chloroethylammonium, benzalkonium chloride, dodecyl dimethyl ethylphenoxyethyl ammonium bromide, guanidine and guanidine polymers, quaternary ammonium salts, silver ions, copper ions, sodium phenylpropionate, nifedipine, dimethyl fumarate, sorbic acid, and dehydroacetic acid. The concentration of the antibacterial agent in water is 0.1 wt%–100 wt%.

The invention relates to the technical field of new application of medicines, and discloses application of nifedipine in preparation of weight-reducing medicines. Specifically, the invention discloses an application of nifedipine in preparation of a product for treating obesity or a product for reducing the weight of animals in a non-disease state, the molecular formula of nifedipine is C17H18N2O6, and experiments find that the weight of obese mice can be effectively reduced through administration treatment of nifedipine; after continuous administration for 8 weeks, the average body weight is reduced by 14.61% relative to the original body weight, and the compound can be used for preparing weight-reducing drugs.

This invention relates to the field of chemical synthesis technology and discloses a method for synthesizing methyl acetoacetate, an intermediate of nifedipine. The method includes: a first pretreatment system preparation step, in which methyl acetoacetate is mixed with a basic catalyst in an aprotic polar solvent, and a free radical scavenger and a complexing stabilizer are added to obtain a pre-activated solution; a second pretreatment system preparation step, in which 3-nitrobenzaldehyde is pre-complexed with a Lewis acid catalyst and a coordination stabilizer is added to obtain a pre-complexed solution; a microchannel rapid mixing reaction step, in which the two pretreatment solutions are rapidly mixed in milliseconds through a microchannel mixer to induce a condensation reaction; and a rapid quenching and product separation step, in which the reaction is immediately quenched at the microchannel outlet and the product is separated. This invention solves the technical problems of low catalytic efficiency, unstable pretreatment solutions, and uneven mixing in traditional methods.

The present application relates to a preparation process of nifedipine preparation, and belongs to the technical field of drug synthesis. In the present application, PEG4000 and PEG1500 are compounded and used as a solid dispersion carrier, and the main components are distributed in the carrier in a molecular state; sodium carboxymethyl starch and corn starch are selected as filling adjuvants, which can significantly improve the dissolution effect of the raw drug, reduce the adsorption of nifedipine, cooperate with the solid dispersion carrier, further eliminate the adsorption of the raw drug molecules, improve the dissolution degree of the drug, and the dissolution speed is fast. The present application further improves the dissolution degree and dissolution rate of the prepared nifedipine preparation, and more than 90% of the nifedipine preparation can be dissolved in 30 minutes, and finally the dissolution effect close to 100% is realized, and the bioavailability of the drug is significantly improved.

The invention belongs to the field of pharmaceutical preparations, and provides a miscarriage prevention medicine for inhibiting uterine contraction and a preparation method of the miscarriage prevention medicine. According to the invention, a double-layer tablet design of a nifedipine-nicotinamide eutectic nanocrystalline quick-release layer and a nifedipine-loaded calcium alginate sustained-release pellet sustained-release layer is adopted, and the median particle size of nifedipine in the quick-release layer is controlled to be 0.10-0.40 [mu] m through a nanocrystallization eutectic technology so as to realize quick effect; meanwhile, nifedipine in a sustained-release layer is continuously released by utilizing a calcium alginate ion cross-linked sustained-release pellet drug-loading technology, so that precise regulation and control of a two-phase release curve and collaborative optimization of interlayer bonding strength are realized, the in-vitro dissolution performance of nifedipine is improved, a release time window is prolonged, the batch-to-batch consistency is improved, and the sustained-release effect of nifedipine is improved. The problems that an existing double-layer preparation is difficult to give consideration to layering resistance and drug release differentiation, the processability and the stability of the eutectic nanocrystalline dispersoid are mutually restricted, the contradiction exists between high drug loading and release controllability of the sustained-release pellet and the like are solved, and wide clinical application value is achieved.

The invention discloses a polydopamine modified nifedipine nano-platform and a preparation method and application thereof, the particle size of the polydopamine modified nifedipine nano-platform is 100-300 nm, the polydopamine modified nifedipine nano-platform is hexagonal, the polydopamine modified nifedipine nano-platform is composed of hollow polydopamine nano-particles serving as a carrier and nifedipine loaded on the hollow polydopamine nano-particles, and the hollow polydopamine nano-particles are prepared through a reaction of ZIF-8 and dopamine. According to the present invention, the drug loading capacity and the tumor targeting capacity are excellent, the tumor cells can be targeted through the EPR effect, and the breast cancer cells can be effectively killed; it is clear that nifedipine inhibits breast cancer through a GnRH signal channel for the first time, and new drug selection and drug combination strategies are provided for breast cancer treatment; the anti-tumor and cardiovascular protection effects are considered, and the risk of cardiovascular complications in the treatment of breast cancer patients can be reduced.

The application discloses a kind of polydopamine modified nifedipine nano platform and its preparation method and application, its particle size is 100-300 nm, present hexagon, by as carrier hollow polydopamine nanoparticle and the nifedipine loaded on it constitute, wherein, hollow polydopamine nanoparticle is made by ZIF-8 and dopamine response.The application has excellent drug loading capacity and the targeting ability to tumor, can target tumor cells by EPR effect, effectively kill breast cancer cells;Firstly, it is clear that nifedipine inhibits breast cancer through GnRH signal pathway, provides new drug selection and combined drug strategy for breast cancer treatment;Give consideration to antitumor and cardiovascular protective effect, possibly reduce the risk of cardiovascular complications in breast cancer patient treatment.

The invention relates to the technical field of chemical synthesis, and discloses a nifedipine intermediate methyl 2-(3-nitrobenzylidene)-acetoacetate synthesis method, which comprises: a first pretreatment system preparation step, the method comprises the following steps: mixing methyl acetoacetate with a basic catalyst in an aprotic polar solvent, and adding a free radical scavenger and a complexing stabilizer to obtain a pre-activated solution; a second pretreatment system preparation step: pre-complexing 3-nitrobenzaldehyde and a Lewis acid catalyst, and adding a coordination stabilizer to obtain a pre-complexing solution; a micro-channel rapid mixing reaction step: carrying out millisecond-level rapid mixing on the two pre-treatment liquids through a micro-channel mixer and carrying out a condensation reaction; and a rapid quenching and product separation step: carrying out a quenching reaction immediately at the outlet of the microchannel and separating the product. The technical problems that a traditional method is low in catalytic efficiency, the pretreatment liquid is unstable, and mixing is uneven are solved.